Pini, Veronica
Mariot, Virginie
Dumonceaux, Julie
Counsell, John
O’Neill, Helen C.
Farmer, Sarah
Conti, Francesco
Muntoni, Francesco
Funding for this research was provided by:
Muscular Dystrophy UK (RA3/3076)
Article History
Received: 27 September 2021
Accepted: 9 February 2022
First Online: 8 March 2022
Competing interests
: F.M. is member of the SAB of Rare Disease Pfizer and of Dyne Therapeutics, and has received speakers honoraria from Sarepta Therapeutics. The remaining authors declare no competing interests.